A new fast-acting insulin biosimilar has been approved to help manage blood sugar in people with diabetes, including both children and adults. This marks a significant milestone in expanding treatment options for individuals who rely on insulin to regulate their glucose levels.
The product, called Merilog, is the first fast-acting insulin biosimilar to receive federal approval. Biosimilars are highly similar to already-approved biologic drugs, offering the same safety, efficacy, and quality while providing a more cost-effective alternative. These options play a crucial role in increasing accessibility to essential medications, particularly for people with chronic conditions such as diabetes.
Understanding Diabetes and Insulin
Diabetes is a metabolic disorder in which blood sugar (or glucose) levels rise too high due to the body’s inability to produce or effectively use insulin. Insulin is a hormone produced by the pancreas that helps move glucose from the bloodstream into cells, where it is used for energy. Without sufficient insulin, blood sugar accumulates, potentially leading to severe health complications.
In the United States, more than 38 million people are living with diabetes, and approximately 8.4 million of them depend on insulin therapy to control their blood sugar levels. Given the high demand for insulin, biosimilars like Merilog can provide patients with more choices, helping to make this essential treatment more affordable and accessible.
How Merilog Works
Merilog is a rapid-acting insulin biosimilar designed to help manage post-meal blood sugar spikes. It works similarly to other fast-acting insulins, such as Novolog, by acting quickly to regulate glucose levels. This insulin is typically taken five to ten minutes before a meal to prevent excessive blood sugar increases after eating.
Like other injectable insulins, Merilog is administered subcutaneously, meaning it is injected just under the skin. The preferred injection sites include the stomach, thighs, buttocks, and upper arms. Proper rotation of injection sites is important to prevent complications such as skin thickening or lumps.
The dosage of Merilog varies based on individual patient needs and should be tailored accordingly. Healthcare providers will determine the appropriate amount based on factors such as blood sugar levels, diet, physical activity, and overall diabetes management plan.
Potential Side Effects
As with any medication, Merilog comes with potential side effects. Common side effects include:
- Skin reactions at the injection site, such as redness, irritation, or changes in skin texture
- Itching or rash
- Weight gain
- Swelling in the hands and feet
While these side effects are generally mild, Merilog can also cause more serious reactions in some patients. These may include:
- Low blood sugar (hypoglycemia): A potentially dangerous condition that occurs when blood sugar levels drop too low, leading to symptoms such as dizziness, confusion, sweating, rapid heartbeat, and in severe cases, loss of consciousness or seizures.
- Low potassium levels (hypokalemia): A drop in potassium levels can lead to muscle weakness, abnormal heart rhythms, and other complications.
- Severe allergic reactions: Some individuals may experience a serious allergic response, which could include difficulty breathing, swelling of the face or throat, and a sudden drop in blood pressure.
Patients using Merilog should be closely monitored, especially when starting treatment or adjusting doses. It is essential to follow healthcare provider recommendations and be aware of signs of adverse reactions.
Expanding Access to Insulin
The approval of Merilog represents a major step toward improving insulin accessibility and affordability. As a biosimilar, it provides a high-quality alternative to existing fast-acting insulins, which can be expensive for many patients. The introduction of more biosimilar insulin options could lead to increased competition in the market, potentially driving down costs and making insulin more affordable for those who need it most.
For millions of people managing diabetes, having additional treatment options like Merilog is a positive development. It offers another tool in the effort to maintain stable blood sugar levels, helping to reduce the risk of complications associated with diabetes. With continued advancements in biosimilar medications, more patients may gain access to life-saving treatments at lower costs, ultimately improving health outcomes for individuals living with diabetes.
